15 % of Black Women to 7 % of White Women are diagnosed with Breast Cancer. Can Genomics be the Tool to low the rate in which black women are dia

15 percent of Black Women to 7 percent of White Women are diagnosed with Breast Cancer. Can Genomics be the tool to low the rate in which black women are diagnosed with Breast Cancer and extend their lives.

We know that there are 194,280 Americans will be diagnosed with breast cancer this year and 40,610 will die from the disease. 15 percent Black to 7 percent White.

Some guidelines recommend that Cancer stem cells is the fuel that grow Breast Cancer tumor's. Others guidelines recommend that bone mineral density is the fuel that grows tumors.
Chemotherapies do not work against these cells, which is why cancer recurs and spreads. Hybrid Medical Analytics believe that eliminating the cancer stem cells is key to controlling cancer.

21 percent of black women and 15 percent of white women do not receive the minimum expected treatment. Black Women have shorter survival and higher mortality observed for black women
compared to white women.The correlation of lower social class and the lack of Health Care equals less screening, and later stage diagnosis.

Can Genomics be the answer for Black women ? Genomics Science looks at groups of genes and how active they are. This activity can influence how a cancer is likely to grow and respond to treatment.
Hybrid Medical Analytics Genomics Science looks at 21 genes in a patient’s breast cancer tumor in trials to understand how these genes interact and influence the tumor’s behavior.

Genomics is personalized treatment that will reduce the rate of cancer for Black Women.

Tamoxifen and Raloxifene works the same for Balck and White Women, but to many Black Women say the treatment can be toxic. Black Women state that too much toxicity leads to not taking the treatment.

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems

Hybrid Medical Analytics CIO Reports Our Sybase Geonomics Glioblastoma Data Mining Shows that the PTPRD Gene shows to be Promising.

Biotech: Hybrid Medical Analytics CIO Reports that our Sybase Geonomics Glioblastoma Data Mining Shows that the PTPRD Gene shows to be Promising.

Three of every 100,000 Americans have been diagnosed with glioblastoma multiforme ....malignant brain tumors. Most patients with glioblastoma die of the disease within approximately 14 months of diagnosis.

Glioblastoma is not a single disease that appears to be four distinct molecular subtypes Cancer Cell,Investigation of targeted Therapies may improve the near uniformly fatal prognosis of this cancer.

The ability to differentiate Glioblastoma Tumors based on their altered genetic code.Using a cancer's genome to unravel the molecular changes. Comprehensive and coordinated effort to accelerate understanding of how molecular can help extend life
based on cancer through the application of genome analysis technologies and large-scale genome sequencing.

Hybrid Medical analysis Geonomics shows the PTPRD mutations in both the blood and in tumors of a patient with Glioblastoma cancers, can be responsible for an inherited susceptibale to Brain Cancer.

Hybrid Medical Analytics Area of Research

* Breast cancer
* Endocrine system cancer
* Gastrointestinal cancer
* Genitourinary cancer
* Gynaecological cancer
* Haematological cancer
* Head and neck cancer
* Neurooncology
* Paediatric oncology
* Thoracic oncology
* Sarcoma
* Skin cancer
* Epidemiology, cancer prevention, and cancer control
* Supportive care
* Imaging
* Health-care systems